MoonLake Immunotherapeutics (MLTX) Net Income towards Common Stockholders (2021 - 2026)

MoonLake Immunotherapeutics' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$69.7 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 71.87% year-over-year to -$69.7 million in Q1 2026; TTM through Mar 2026 was -$259.5 million, a 75.52% decrease from a year earlier, with the FY2025 full-year figure at -$230.3 million, down 89.96% from the prior year.
• Net Income towards Common Stockholders eased to -$69.7 million in Q1 2026 per MLTX's latest filing, from -$63.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$7.9 million in Q4 2023 and bottomed at -$70.7 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$17.4 million (2022), against an average of -$31.2 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 69.3% in 2022; the steepest drop was 20715.22% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$16.5 million in 2022, then jumped by 52.11% to -$7.9 million in 2023, then tumbled by 488.23% to -$46.4 million in 2024, then plunged by 35.83% to -$63.0 million in 2025, then retreated by 10.61% to -$69.7 million in 2026.
• Per Business Quant, the three latest MLTX Net Income towards Common Stockholders figures stand at -$69.7 million (Q1 2026), -$63.0 million (Q4 2025), and -$70.7 million (Q3 2025).